Notice of Clarification to the High-Risk, High-Reward Research Program: Pioneer: RFA-RM-20-011, New Innovator: RFA-RM-20-012, Transformative Research (RFA-RM-20-013, RFA-RM-20-020 & NOT-RM-20-019), and Early Independence (RFA-RM-20-014 & RFA-RM-20-021)
Notice Number:
NOT-RM-21-004

Key Dates

Release Date:

October 5, 2020

Related Announcements

NOT-OD-20-123 - Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
NOT-OD-20-163 - Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
NOT-RM-20-019 - Notice of Special Interest (NOSI): Common Fund ALS-related Transformative Research Award (R01 Clinical Trial Optional)
RFA-RM-20-011 - NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)
RFA-RM-20-012 - RFA-RM-2NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)
RFA-RM-20-013 - NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
RFA-RM-20-014 - NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)
RFA-RM-20-020 - NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)
RFA-RM-20-021 - NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional)

Issued by

Office of Strategic Coordination (Common Fund)

Purpose

The purpose of this Notice is to inform applicants to the High-Risk, High-Reward Research (HRHR) program’s FY2021 funding opportunity announcements that the Special Exception to NIH Post-Submission Material Policy During the COVID-19 Pandemic will not apply to applications submitted to:

Preliminary data are not required or expected for HRHR applications. Rather, HRHR proposals are expected to focus on the importance of the problem, novelty of the approach, and potential impact. Due to the special preliminary data limitations for applications submitted to HRHR initiatives, post submission of preliminary data will not be allowed for HRHR applications.

Inquiries

Please direct all inquiries to:

Ravi Basavappa, Ph.D.
Office of the Director (OD)
Telephone: 301-435-7204
Email: [email protected]


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices